Market Highlights
Get the latest Indian stock / share market highlights, BSE/NSE stock news, business research reports & details - updated daily by Money Times.
July 03, 2025
- Daily Morning Report Date: 3rd July 2025
- NIFTY OUTLOOK: 25453.40 FII: -1561.62 cr DII: 3036.68 cr
- As discussed yesterday, market behaviour remained on expected lines. Selling pressure dragged the Nifty down to our support of 25373 (made a low of 25379) after a decisive breakdown of 25486.
- An average bearish candle appeared on the daily chart, suggesting that if Nifty decisively breaks below 25397, further weakness may extend to 25341–25286. If selling intensifies, it may test 25230.
- On the upside, 25510–25565 may act as immediate resistance. A breakout above these levels and sustained move may push Nifty towards 25621–25677.
- Bank Nifty OUTLOOK
- SPOT: 56999.20 PCR: 1.09 Max CE OI: 56000 Max PE OI: 56000
- On 2nd July 2025, Bank Nifty closed at 56999.20, down 0.80% from the previous close.
- The index moved 794.60 points during the session, with a high of 57628.40 and a low of 56833.80.
- Technical View on Daily Chart:
- Key support and resistance levels are at 56500 and 57900, respectively.
- Intraday Strategy:
- Go Long above 57210 with SL 57145 and target 57435
- Go Short below 56780 with SL 56850 and target 56560
- The RSI stands at 59.60 (below 30 is oversold, above 70 is overbought).
- SMA Analysis:
- Bank Nifty is trading above 7 out of 8 SMAs (10, 20, 30, 50, 100, 150, 200-day) and below the 5-day SMA.
- No active candlestick pattern identified.
- Macros.
- 1. Dollar index @ 96.455
- 2. Vix @16.64
- 3. Crude @ 68.57
- 4. US 10 years bond yield @ 4.261
- Note:
- Markets worldwide remain subdued as the 9th July deadline approaches. Trump has confirmed he won’t extend it, indicating that if no deal is reached, formal letters detailing tariff rates will be issued to affected nations.
- The impact of tariffs is becoming evident in China and other economies. Recent data showed that China’s services sector grew at its slowest pace in nine months in June. Additionally, Australia’s trade surplus narrowed more than expected in May, hitting its lowest since November 2019, with weak global demand affecting exports and imports rebounding from prior declines.
- Strategy:
- Remain cautious and adopt a wait-and-watch approach for the next 4–5 days.
- Contributed by
- Ashok bhandari : INH000019549
- -------------------------------------xxxxxxx-------------------------------------------------------------------xxxxxxx---------------------------------
- *COLGATE, BUTTERFLY GANDHIMATHI, TTK PRESTIGE, STOVE KRAFT, SINGER INDIA, FOOTWEAR, FMCG, CERAMIC STOCKS: Govt may cut GST on household items from 12% to 5%*
- Likely affected products include toothpaste, pressure cookers, footwear, sewing machines, and ceramic tiles.
- *The move aims to lower prices and boost consumption among middle and lower-income households*.
- CLSA ON DMART
- (CMP: ₹4,391.90)
- MAINTAIN : OUTPERFORM
- TARGET PRICE: ₹5,549
- Reported Q1 Standalone Revenues 2% Below Estimates
- Co Added Nine New Stores During The Quarter (Versus Six Stores In Q1FY25)
- Total Store Count At 424 At The End Of Q1FY26
- CITI ON PNB (CMP:113.85)
- MAINTAIN SELL
- TARGET PRICE: ₹101
- Reported Gross Advances Growth Of 9.9% YoY/1.3% QoQ (Vs Est Of 2.1% QoQ)
- Expect Ram Segments To Be Primary Growth Driver
- Deposits Growth Stood Marginally Below Est
- Shakti Pumps:
- Co Plans QIP Launch With Set Floor Price of ₹965.96
- @beatthestreet10
- Asahi India Glass : Promoter Ashok Kanhayalal Monga sold 12,000 shares.
- @beatthestreet10
- Star Cement : Promoter Vinay and Co. sold 1228 shares, Promoter Suchita Agarwal sold 9,500 shares
- @beatthestreet10
- Incred on Adani Power
- Initiate ADD, TP Rs 649
- Co targets 75% capacity growth to 30.67GW by FY30F, aligning with India’s 5-6% power demand growth to meet projected 458GW peak by FY32F
- 87% of Co’s capacity is tied to long-term PPAs delivering Rs200bn of recurring EBITDA in FY25
- 17% of sales volume is from merchant power, capitalizing on high-margin opportunities
- Capex of Rs1,200bn is expected to be funded via internal accruals, deleveraging b/s to reduce net-debt/EBITDA to 0.9x by FY30F from 1.5x in FY25
- Downside risks: Execution delay in the 13.12GW pipeline, lower-than-expected merchant realization and revival of discom payment issue.
- @beatthestreet10
- IL&FS BKC OFFICE IN CLIFFHANGER
- IL&FS moves NCLT to scrap Brookfield’s Rs 1,080-crore bid for Mumbai headquarters.
- https://bit.ly/44dOjgH
- CLSA on Avenue Supermart
- O-P, TP Rs 5549
- reported standalone revenues of Rs159,321m for 1QFY26 (2% below estimates).
- Sales growth for the quarter stood at 16.2% YoY (versus 16.7%/17.5%/14.2% in 4QFY25/3QFY25/2QFY25 respectively)
- Co added nine new stores during quarter
- Biocon : Co. Gets EU Nod for Denosumab Biosimilars
- - Positive Impact
- EU Approval Boost: European Commission grants marketing authorization for Vevzuo® and Evfraxy®, biosimilars of Denosumab, for treating osteoporosis and cancer-related bone loss.
- Therapeutic Expansion: Marks Biocon Biologics’ entry into the bone health segment—expanding therapeutic portfolio.
- Regulatory Momentum: Third biosimilar approval in EU in 18 months, demonstrating strong regulatory execution and pipeline strength.
- Market Opportunity: Targets large patient population across Europe—32 million osteoporosis cases in 50+ age group (2019 data).
- Commercial Leverage: Enhances global biosimilars portfolio with applications in oncology and orthopedics.
- WARDWIZARD INNOVATIONS : PROMOTER SOLD 2.33 % STAKES ON 27 ,30 th JUNE VIA OPEN MARKET
- Jefferies on GMR Airports
- Buy, TP Rs 100
- TDSAT recently quashed AERA’s earlier HRAB calculation for DIAL Airport, further directing a fresh computation
- HRAB, a notional asset base, is key to setting aero tariffs, & TDSAT has held AERA's method as incorrect to calculate HRAB
- If final ruling favors DIAL, revised HRAB could significantly raise allowable tariff recovery due to past under-recoveries
- This &other debated under-recoveries could mean major upside to DIAL tariff/profitability
- Vedanta: Vedanta Demerger Faces NCLT Delay Amid Regulatory Review
- NCLT Hearing Deferred: Petroleum Ministry seeks more time to review the demerger; next hearing set for August 20.
- SEBI & NSE Input: SEBI is still verifying compliance, while NSE has already granted a No Objection Certificate.
- Process Uncertainty: Delay adds regulatory overhang and uncertainty to the timeline of Vedanta's restructuring.
- Strategic Plans Unchanged: Vedanta reiterates commitment to its demerger and reorganization strategy.
- Negative Impact (Short-Term): Delay may pressure investor sentiment and stock performance in the near term
- GOLDMAN SACHS ON CONSUMER STAPLES
- Govt Considering Eliminating 12% GST Slab & Reclassifying Them In 5% Slab, As Per Reports
- Apparel & Footwear Products Currently At 12% GST; Trent & Bata In Focus
- Packaged Foods & Beverages Currently At 12% GST Include Nestle's Condensed Milk, Confectionery
- CLSA ON DMART
- (CMP: ₹4,391.90)
- MAINTAIN OUTPERFORM
- TARGET PRICE: ₹5,549
- Reported Q1 Standalone Revenues 2% Below Estimates
- Co Added Nine New Stores During The Quarter (Versus Six Stores In Q1FY25)
- Total Store Count At 424 At The End Of Q1FY26
- MACQUARIE ON DMART
- (CMP:₹4,391.90)
- MAINTAIN UNDERPERFORM
- TARGET PRICE: ₹3,000
- Q1 Sales Growth Moderated Slightly From Q4
- Marginal Miss On Sales Growth
- Healthy Pace Of Store Additions
- Typically, Q1 Sees A Stronger Gross Margin Given Product Mix
- Hence, Assume A Sequential Uptick In Gross Margin & EBITDA Margin
- CITI ON SAIL
- (CMP:137.48)
- MAINTAIN SELL
- TARGET PRICE: ₹115
- Revise Estimates Upwards Based On Recent Trends & Mgmt Commentary
- However, Believe That 1Q EBITDA/t Should Likely Be Peak & Already Disc In Stk Price
- Steel Prices Could Correct Further Given Demand-Supply Trends
- Spot EBITDA/t Would Imply Co Currently Trades At EV/EBITDA Multiple Of 7x
- Expect Further Downside To Steel Prices And EBITDA/t To Correct Further
- Incred on Adani Power
- Initiate ADD, TP Rs 649
- Co targets 75% capacity growth to 30.67GW by FY30F, aligning with India’s 5-6% power demand growth to meet projected 458GW peak by FY32F
- 87% of Co’s capacity is tied to long-term PPAs delivering Rs200bn of recurring EBITDA in FY25
- 17% of sales volume is from merchant power, capitalizing on high-margin opportunities
- Capex of Rs1,200bn is expected to be funded via internal accruals, deleveraging b/s to reduce net-debt/EBITDA to 0.9x by FY30F from 1.5x in FY25
- Downside risks: Execution delay in the 13.12GW pipeline, lower-than-expected merchant realization and revival of discom payment issue.
- GOVT SOURCES SAY Interim Trade Deal Could Be Signed With US Within The Next Two Days - CNBCTV 18
- Negotiations For Concluding An Interim Trade Deal B/w India & The US Are In Final Stages
- Indian Officials Are Demanding Greater Access For Labour Intensive Industries
- Cannot Open Agri & Dairy Sectors Completely; Ltd Access In Some Areas May Be Allowed
- India Will Not Compromise On Interests Of Farmers
- UBS on NBFCS
- Growth to keep moderating, limited (asset quality) improvement
- Cost of funds could see a small decline sequentially
- Commentary on asset quality, cost of fund and growth are key
- Top picks are Chola Finance, PFC and PNB Housing
- GOLDMAN SACHS ON CONSUMER STAPLES
- Govt Considering Eliminating 12% GST Slab & Reclassifying Them In 5% Slab, As Per Reports
- Apparel & Footwear Products Currently At 12% GST; Trent & Bata In Focus
- Packaged Foods & Beverages Currently At 12% GST Include Nestle's Condensed Milk, Confectionery
- Kotak India Strategy
- Insiders out, outsiders in
- Sharp increase in exits of insiders one half of the story
- Price-agnostic buying by retail shareholders the other half of the story
- Price-agnostic buying of retail investors continues; retail sentiment better
- DIIs and retail investors have increased their stake in this exchange
- MS India Strategy
- Fundamentals are as strong as ever
- Fundamentals Not in the Price
- India is expectedly underperforming the ongoing global equity bull market
- Medium to long-term story stacks up strongly in India’s favor to beat Emerging Market and Asian equities
- India remains one of preferred plays
- Domestic Cyclicals > Defensives and External-facing sectors
- Overweight - Financials, Consumer Discretionary, and Industrials
- Underweight - Energy, Materials, Utilities, and Healthcare
- This is likely to be a stock pickers' market, in contrast to one driven by top-down or macro factors since the Covid pandemic
- We are capitalization-agnostic
- GOVT SOURCES SAY Interim Trade Deal Could Be Signed With US Within The Next Two Days - CNBCTV 18
- Negotiations For Concluding An Interim Trade Deal B/w India & The US Are In Final Stages
- Indian Officials Are Demanding Greater Access For Labour Intensive Industries
- Cannot Open Agri & Dairy Sectors Completely; Ltd Access In Some Areas May Be Allowed
- India Will Not Compromise On Interests Of Farmers
- SONA BLW ; ICICI PRUDENTIAL BOUGHT ADDITIONAL 0.06 % STAKE ON 1 JULY VIA OPEN MARKET
- SONA BLW ; ICICI PRUDENTIAL BOUGHT ADDITIONAL 0.06 % STAKE ON 1 JULY VIA OPEN MARKET
- STAKE INCREASED TO 5.05 % FROM 4.99 % EARLIER
- CHINA MANUFACTURING DATA
- Caixin June Services PMI 50.6[Est. 50.9 Prev. 51.1]
- Caixin June Composite PMI 51.3[Prev. 49.6]
- *SERVICES PMI WEAKEST SINCE OCT 2024.
- ASIAN MARKET SECURITIES ON BHARAT ELECTRONICS
- Initiates 'Buy' Rating With Target Price At ₹550 (30% Upside)
- Steady Execution Of Current Order Book To Drive Growth Momentum
- Dominant Leader And Platform Integrator Across Defence Ecosystem
- Direct Leverage To Increasing Defence Budget Alloc Defence Ecosystem
- METALS: China’s services PMI fell to 50.6 in June, marking the slowest growth since September 2022.
- New export orders saw the steepest drop since December 2022, reflecting weakening global demand.
- Ongoing price cuts and reduced hiring signal pressure on industrial activity, dampening the metals outlook.
- ALEMBIC PHARMA: The company has acquired US-based Utility Therapeutics to strengthen its urinary tract infection (UTI) portfolio.
- The deal includes rights to USFDA-approved drug “Pivya” and another UTI candidate in development.
- Structured at ~$12 million with profit-sharing, the move boosts Alembic’s US market strategy.
- BHARAT FORGE, BALKRISHNA IND, RAMKRISHNA FORGINGS, MM FORGINGS: North America Class 8 truck orders fell 25% MoM and 36% YoY in June.
- Orders declined to 8,900 units from 12,000 units in May.
- The sharp drop signals weakening demand in the commercial vehicle segment.
- Tata Group in talks to buy out other shareholders in Singapore-based resurgent power ventures - NDTV PROFIT
- Tata Power working with adviser to Buy stakes held by ICICI Venture, ΚΙΑ, ΟΙΑ
- ICICI Venture, KIA & OIA hold 74% in resurgent, seeking a valuation of about $2.1 Bn
- Macquarie double downgrade IndusInd Bank
- Downgrade to Underperform from Outperform; Cut TP to Rs 650 from Rs 1210
- NUVAMA Says HUL Likely To Report 3% Volume Growth In Q1 V 2 % Previously
- Prefer UBL Το USL In Alcobev Space, Like Bikaji & Nestle
- Marico Volume Growth Seen Around 7%
- Believe Paint Stocks Have Bottomed Out From A Long-term Stand Point
- All Parameters Around Consumption Are Improving
- Possible GST Rationalisation Could Further Aid Low Ticket Consumption
- BHARAT FORGE : Kalyani Group Explores Development of 155mm/52-Caliber Tracked Self-Propelled Howitzer Based on ATAGS - IDRW
- GMR Power
- Vistra released 25 million GMR Power shares from encumbrance on June 30, 2025, reducing pledge to 11.19%
- DIVIS LAB: Divis Labs to manufacture intermediates for Merck’s peptide drug Enlicitide.
- The drug is projected to reach $3–5 billion in peak sales, with Divis’ opportunity estimated at over $90 million.
- This supports long-term growth for Divis’ Custom Synthesis business.
- BLUESTAR MD Says Q1 Was A Bad Quarter For RAC, Commercial AC Segment Performed Well
- Q1 RAC Industry Should See Growth Of 25% YoY
- GAIL ; PNGRB to move with Independent natural gas transport system operator likely soon, as per reports
- Currently managed by GAIL and GSPL
- Analysts Say
- The impact is likely to be felt more keenly for GAIL
- Gas marketing margins could compress owing to more competition and higher regulatory oversight
- The move will be a negative for GAIL, with potential risks to business structure and earnings mix
- BLUESTAR MD Says Stick To 10-15% Revenue Growth Guidance For FY26
- V2RETAIL Management Says Seeing Demand Pressure In Rural Market Over Last 2 Years
- Pick-Up In Rural Demand, Economic Growth Of Tier II & III Cities To Further Aid Performance
- Do Not Pian To Premiumise Our Collection
- HDB FINANCIAL UP 5 %
- Ionic Wealth Chartbook : Decoding FY25 Earnings
- Very interesting charts and data insights
- https://www.linkedin.com/posts/ionic-wealth_decoding-earnings-trendsionic-wealth-chartbook-activity-7346064303688450048-dPOz?utm_source=share&utm_medium=member_android&rcm=ACoAACQE6cABfIpO4XwiH2BFl3ArbnAd2Yb68So
- Linkedin (https://www.linkedin.com/posts/ionic-wealth_decoding-earnings-trendsionic-wealth-chartbook-activity-7346064303688450048-dPOz?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQE6cABfIpO4XwiH2BFl3ArbnAd2Yb68So)
- V2RETAIL Management Says May increase Store Opening Guidance
- Aim To increase Profit By Focusing On Sales/Sq Ft - NDTV PROFIT
- BLUE CLOUD: Co. launches AI-powered 'BluHealth' platform targeting clinical decision support and remote diagnostics.
- Platform eyes $6 million revenue opportunity with focus on underserved global regions.
- Supports HIPAA/GDPR compliance and includes next-gen health tech for scalable deployment.
- GARMENT MANTRA: Subsidiary Hylex Fashion secures ₹10.13 Cr export order from Dubai-based AL Rahmat Textiles.
- The deal involves dress materials and fabrics to be delivered by March 2026.
- Marks Garment Mantra’s strategic expansion into the Middle East market.
- GARMENT MANTRA: Subsidiary Hylex Fashion secures ₹10.13 Cr export order from Dubai-based AL Rahmat Textiles.
- The deal involves dress materials and fabrics to be delivered by March 2026.
- Marks Garment Mantra’s strategic expansion into the Middle East market.
- KARNATAKA BANK Management Says Have Recommended Interim MD To RBI & Waiting For An Approval
- RBI Approval On MD Recos Should Come In Before July 15 - CNBCTV18
- INDIA, MOST EXPENSIVE MARKET ; CLSA
- CLSA Viksa Jain Says With a 2-year EPS CAGR of 11%, Nifty's earnings growth is now mediocre but India has again become the most expensive market in the world on PE and at a very rich premium versus EMs, Asia ex-Japan and China.
- Nifty's valuation vs bonds is below the danger mark and investor sentiment still in the neutral zone per our proprietary India Bull-Bear Index and this may be the silver lining for the bulls.
- We add Bajaj Auto to Bull-Bear Index and this may be the silver lining for the bulls.
- We add Bajaj Auto to our portfolio and remove Britannia.
- CLSA Says A combination of extended valuations and risk of earning downgrades makes us cautious on near-term returns.
- We prefer defensives downgrades makes us cautious on near-term returns.
- We prefer defensives alongwith autos, energy, realty and banks
- DEFENCE STOCKS: India and US to sign a 10-year Defence Framework Agreement in upcoming bilateral talks.
- Focus on joint R&D, co-production, and tech transfer to strengthen defence ties.
- Companies like BEL, HAL, Bharat Dynamics, and MTAR may see improved visibility and collaboration prospects.